VTRS

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Dollar change -0.29
Percentage change -3.07	%

Peers: PFE MRK BMY JNJ ABBV GSK LLY AMGN SNY NVS

| Held by: VTI VOO VO RSP SPY IVV CALF VTV XLV VOE

Index	S&P 500	P/E	-	EPS (ttm)	-0.53	Insider Own	2.55%	Shs Outstand	1.19B	Perf Week	0.55%
Market Cap	10.92B	Forward P/E	3.79	EPS next Y	2.42	Insider Trans	-0.07%	Shs Float	1.16B	Perf Month	-17.27%
Income	-634.20M	PEG	-	EPS next Q	0.51	Inst Own	82.74%	Short Float	2.29%	Perf Quarter	-27.32%
Sales	14.68B	P/S	0.74	EPS this Y	-16.47%	Inst Trans	4.15%	Short Ratio	2.12	Perf Half Y	-23.11%
Book/sh	15.61	P/B	0.59	EPS next Y	9.16%	ROA	-1.42%	Short Interest	26.65M	Perf Year	-22.91%
Cash/sh	0.69	P/C	13.17	EPS next 5Y	-0.80%	ROE	-3.24%	52W Range	8.77 - 13.55	Perf YTD	-26.51%
Dividend Est.	0.53 (5.84%)	P/FCF	5.52	EPS past 5Y	-	ROI	-1.93%	52W High	-32.47%	Beta	0.89
Dividend TTM	0.48 (5.25%)	Quick Ratio	0.89	Sales past 5Y	8.72%	Gross Margin	39.87%	52W Low	4.33%	ATR (14)	0.34
Dividend Ex-Date	Mar 10, 2025	Current Ratio	1.56	EPS Y/Y TTM	-1269.23%	Oper. Margin	7.16%	RSI (14)	34.37	Volatility	3.05% 3.64%
Employees	32000	Debt/Eq	0.77	Sales Y/Y TTM	-4.58%	Profit Margin	-4.32%	Recom	2.64	Target Price	11.17
Option/Short	Yes / Yes	LT Debt/Eq	0.76	EPS Q/Q	32.18%	Payout	1059.60%	Rel Volume	6.21	Prev Close	9.44
Sales Surprise	-2.00%	EPS Surprise	-5.59%	Sales Q/Q	-9.11%	Earnings	Feb 27 BMO	Avg Volume	12.57M	Price	9.15
SMA20	-5.25%	SMA50	-13.32%	SMA200	-20.05%	Trades		Volume	71,873,384	Change	-3.07%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-19-24	Resumed	Jefferies	Buy	$15
Oct-23-23	Downgrade	BofA Securities	Neutral → Underperform	$13 → $9
Jun-23-23	Downgrade	Barclays	Equal Weight → Underweight	$11
Apr-24-23	Downgrade	Barclays	Overweight → Equal Weight	$11
Feb-17-23	Downgrade	BMO Capital Markets	Outperform → Market Perform	$16 → $14
Jan-27-23	Upgrade	Jefferies	Hold → Buy	$13 → $15
Nov-10-22	Upgrade	UBS	Sell → Neutral	$9 → $12
Nov-08-22	Upgrade	Piper Sandler	Underweight → Neutral	$10
Oct-21-22	Resumed	Jefferies	Hold	$11
Jun-14-22	Initiated	UBS	Sell	$9
May-10-22	Downgrade	Piper Sandler	Neutral → Underweight	$10
Mar-01-22	Downgrade	Raymond James	Outperform → Mkt Perform
Mar-01-22	Downgrade	BofA Securities	Buy → Neutral	$21 → $13
Jun-15-21	Initiated	Citigroup	Neutral	$16
Apr-07-21	Resumed	RBC Capital Mkts	Outperform	$24
Mar-08-21	Downgrade	Goldman	Buy → Neutral	$20 → $15
Mar-02-21	Downgrade	JP Morgan	Overweight → Neutral	$21 → $18
Feb-26-21	Downgrade	Wolfe Research	Outperform → Peer Perform	$17
Jan-05-21	Initiated	Argus	Hold
Dec-14-20	Initiated	Bernstein	Mkt Perform	$21

Show Previous Ratings

Mar-21-25 01:32PM	Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility Hagens Berman (GlobeNewswire)
Mar-18-25 03:25PM	Viatris Inc. (VTRS) Faces Investor Scrutiny After Possible Disclosure Delay About June 2024 FDA Inspection of Manufacturing Facility - Hagens Berman (Newsfile)
05:01AM	Q4 Earnings Roundup: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Segment (StockStory)
Mar-17-25 03:26PM	Is Viatris Inc. (VTRS) the Best Nasdaq Stock Under $20 to Buy Now? (Insider Monkey)
Mar-13-25 05:01AM	Q4 Earnings Highs And Lows: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs The Rest Of The Generic Pharmaceuticals Stocks (StockStory)
09:01AM	Loading…
Mar-11-25 09:01AM	1 Healthcare Stock to Target This Week and 2 to Turn Down (StockStory)
Mar-09-25 08:32PM	Why Viatris Inc. (VTRS) Is Plunging So Far In 2025 (Insider Monkey)
Mar-05-25 04:30PM	Viatris to Present at the Barclays 27th Annual Global Healthcare Conference (PR Newswire)
04:03AM	Generic Pharmaceuticals Stocks Q4 In Review: Amneal (NASDAQ:AMRX) Vs Peers (StockStory)
Mar-01-25 02:54PM	Is Viatris Inc. (VTRS) the Best Weight Loss Drug Stock to Buy According to Analysts? (Insider Monkey)
Feb-28-25 07:30PM	Here's What Key Metrics Tell Us About Viatris (VTRS) Q4 Earnings (Zacks)
09:40AM	Why Viatris Inc. (VTRS) Went Down on Thursday (Insider Monkey)
02:28AM	Q4 2024 Viatris Inc Earnings Call (Thomson Reuters StreetEvents)
02:16AM	Viatris Inc (VTRS) Q4 2024 Earnings Call Highlights: Strong Cash Flow and Debt Reduction Amid ... (GuruFocus.com)
Feb-27-25 04:33PM	Analyst Report: Viatris Inc. (Morningstar Research) -15.21%
04:33PM	Loading…
04:33PM	S&P 500 Gains and Losses Today: Nvidia Leads Chip, AI Stocks Lower (Investopedia)
03:06PM	Why Viatris (VTRS) Shares Are Falling Today (StockStory)
01:27PM	eBay, Rolls-Royce, Viatris: Market Minute (Yahoo Finance Video)
11:02AM	Viatris plummets sharply on disappointing fourth-quarter, 2025 outlook (Investing.com)
08:52AM	Is Viatris Inc. (VTRS) the Best Low Price Pharma Stock to Invest In Right Now? (Insider Monkey)
08:35AM	Viatris Shares Decline After Earnings Miss, Lower 2025 Guidance (GuruFocus.com)
07:55AM	Viatris (VTRS) Q4 Earnings and Revenues Lag Estimates (Zacks)
07:11AM	Viatris (NASDAQ:VTRS) Misses Q4 Revenue Estimates, Stock Drops (StockStory)
07:02AM	Viatris: Q4 Earnings Snapshot (Associated Press Finance)
06:45AM	Viatris Reports Fourth Quarter and Full Year 2024 Financial Results and Provides 2025 Financial Guidance (PR Newswire)
06:30AM	Viatris Maintains Dividend Policy for 2025 and Announces Quarterly Dividend (PR Newswire)
Feb-26-25 12:13PM	Viatris Inc. (NASDAQ:VTRS): A Bull Case Theory (Insider Monkey)
12:03PM	Idorsias Tryvio deal collapses, forcing company to find cash urgently (Pharmaceutical Technology)
08:12AM	Viatris Earnings: What To Look For From VTRS (StockStory)
Feb-24-25 09:16AM	Stay Ahead of the Game With Viatris (VTRS) Q4 Earnings: Wall Street's Insights on Key Metrics (Zacks)
04:07AM	Loading…
Feb-21-25 04:07AM	Q3 Earnings Outperformers: Viatris (NASDAQ:VTRS) And The Rest Of The Generic Pharmaceuticals Stocks (StockStory)
Feb-20-25 10:00AM	Earnings Preview: Viatris (VTRS) Q4 Earnings Expected to Decline (Zacks)
Feb-19-25 10:45AM	Uniting Against AMR: Global Solutions Need Local and Global Collaboration (ACCESSWIRE)
04:01AM	Generic Pharmaceuticals Stocks Q3 Teardown: Amneal (NASDAQ:AMRX) Vs The Rest (StockStory)
Feb-18-25 04:35AM	3 Reasons to Sell VTRS and 1 Stock to Buy Instead (StockStory)
Feb-17-25 04:45PM	50 Years of Service: From Milkman's Son to Advancing Access to Medicines (ACCESS Newswire)
Feb-14-25 04:01AM	Unpacking Q3 Earnings: Amphastar Pharmaceuticals (NASDAQ:AMPH) In The Context Of Other Generic Pharmaceuticals Stocks (StockStory)
Feb-13-25 04:01AM	ANI Pharmaceuticals (NASDAQ:ANIP): Strongest Q3 Results from the Generic Pharmaceuticals Group (StockStory)
Feb-03-25 04:30PM	Viatris to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 (PR Newswire)
Jan-22-25 07:02PM	Analyst Report: Viatris Inc. (Morningstar Research)
Jan-20-25 09:10PM	Why Is Viatris Inc. (VTRS) Among the Best High-Yield Dividend Stocks to Invest In? (Insider Monkey)
Jan-16-25 12:06AM	Is Viatris Inc. (VTRS) Among Wednesday's Losers? (Insider Monkey)
Jan-15-25 05:02PM	S&P 500 Gains and Losses Today: Bank Earnings, Soft Inflation Help Boost Index (Investopedia)
09:40AM	Is Viatris (VTRS) a Great Value Stock Right Now? (Zacks)
Jan-12-25 09:42AM	Is Viatris (VTRS) the Best Medical Stock to Buy Under $20? (Insider Monkey)
Jan-07-25 06:59AM	Viatris to Present at the 43rd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-19-24 03:44AM	What Makes Viatris (VTRS) a Favorite Stock for Billionaire David Einhorn? (Insider Monkey)
Dec-18-24 06:59AM	Viatris Announces Publication of Phase 2b CARE Study Data for Cenerimod in Lancet Rheumatology (PR Newswire)
Dec-02-24 08:30AM	Mapi Pharma is Seeking New Depot Product Partnerships (GlobeNewswire)
Nov-21-24 08:51AM	Viatris fined in Morocco over merger notification, sources say (Reuters)
Nov-11-24 11:01AM	ALK snags EU and Canada rights to anaphylaxis nasal spray Neffy for $145m (Pharmaceutical Technology)
Nov-08-24 02:14AM	Viatris Inc (VTRS) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ... (GuruFocus.com)
Nov-07-24 05:02PM	S&P 500 Gains and Losses Today: Index Ticks Higher as Fed Trims Benchmark Rate (Investopedia) +13.52%
04:46PM	Analyst Report: Viatris Inc. (Morningstar Research)
09:30AM	Viatris (VTRS) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
08:25AM	Viatris (VTRS) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:27AM	Viatris: Q3 Earnings Snapshot (Associated Press Finance)
06:59AM	Viatris Reports Third Quarter Financial Results for 2024 (PR Newswire)
Nov-05-24 06:59AM	Viatris Announces Third Quarter 2024 Dividend (PR Newswire)
Nov-04-24 09:16AM	Unveiling Viatris (VTRS) Q3 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Oct-29-24 12:00PM	Viatris Named to Forbes' World's Top Companies for Women 2024 List (PR Newswire)
09:00AM	Viatris to Participate in the UBS Global Healthcare Conference and Jefferies London Healthcare Conference (PR Newswire)
02:00AM	Idorsia announces financial results for the first nine months of 2024 (GlobeNewswire)
Oct-17-24 07:15AM	Lexicon sells Viatris rights to cardio drug outside of the U.S. and Europe (BioPharma Dive)
05:55AM	Lexicon partners Viatris for global expansion of sotagliflozin (Pharmaceutical Technology)
Oct-16-24 04:35PM	Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe (GlobeNewswire)
04:34PM	Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe (PR Newswire)
Oct-15-24 06:27PM	Viatris Settles Lawsuit, Avoids Antitrust Charges, and Advances Effexor Study (GuruFocus.com)
Oct-14-24 01:40PM	Viatris Inc. (VTRS): David Einhorns Top Stock Pick (Insider Monkey)
Oct-12-24 11:16AM	Viatris Inc. (VTRS): A Strategic Shift in Healthcare Investments (Insider Monkey)
Oct-10-24 10:15AM	Viatris 2023 Sustainability Report: Reducing Packaging Material (ACCESSWIRE)
Oct-09-24 05:38PM	Viatris Inc (VTRS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Innovations (GuruFocus.com)
06:59AM	Viatris Announces Positive Top-line Results from Phase 3 Study of EFFEXOR in Japanese Adults with Generalized Anxiety Disorder (GAD) (PR Newswire)
Oct-08-24 03:40PM	Viatris Named to Forbes' Annual List of the World's Best Employers for the Fourth Year in a Row (ACCESSWIRE)
11:23AM	Is Viatris Inc. (NASDAQ:VTRS) The Best NASDAQ Stock Under $20? (Insider Monkey)
Oct-07-24 04:15PM	Viatris 2023 Sustainability Report: Expanding Contractor Training (ACCESSWIRE)
Oct-01-24 10:50AM	Is Viatris Inc. (VTRS) the Best Stock Under $15 To Buy Now? (Insider Monkey)
Sep-30-24 06:59AM	Viatris launches (Pr)Viagra® ODF in Canada: a new oral dissolving film form of the erectile dysfunction treatment (PR Newswire)
Sep-19-24 01:25PM	In Europe, Packaging Site Takes Flight as a Bird-Friendly Workplace (ACCESSWIRE)
11:05AM	Viatris 2023 Sustainability Report: Health and Safety in the Workplace (ACCESSWIRE)
Sep-18-24 11:30AM	Viatris Announces the Pricing Terms of Maximum Tender Offer (PR Newswire)
Sep-17-24 08:45PM	Viatris Announces Early Tender Results and Increase of Pending Maximum Tender Offer (PR Newswire)
Sep-16-24 04:30PM	Viatris to Report Third Quarter 2024 Financial Results on November 7, 2024 (PR Newswire)
10:45AM	From Opposite Ends of the Earth, the Same Story: Women Push for Positive Change (ACCESSWIRE)
09:04AM	Do Options Traders Know Something About Viatris (VTRS) Stock We Don't? (Zacks)
Sep-12-24 10:15AM	Viatris 2023 Sustainability Report: Advocating for Patients (ACCESSWIRE)
Sep-10-24 07:00PM	Viatris Announces Expiration and Results of Any and All Cash Tender Offers (PR Newswire)
11:40AM	Viatris Announces the Pricing Terms of Pending Any and All Cash Tender Offers (PR Newswire)
Sep-09-24 10:15AM	Viatris 2023 Sustainability Report: Breaking Down Systemic Barriers To Access Through Policy Engagement (ACCESSWIRE)
Sep-04-24 11:55AM	Viatris 2023 Sustainability Report: Continued Innovation for Infectious Disease (ACCESSWIRE)
03:30AM	Viatris Announces Cash Tender Offers for Certain Outstanding Notes (PR Newswire)
Sep-02-24 06:33AM	ESC 2024: Single-pill hypertension combo delivers positive results (Pharmaceutical Technology)
Aug-23-24 06:59AM	Viatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress (PR Newswire)
Aug-20-24 05:30AM	3 Top Value Stocks to Buy Right Now (Motley Fool)
Aug-09-24 09:30AM	Compared to Estimates, Viatris (VTRS) Q2 Earnings: A Look at Key Metrics (Zacks)
01:05AM	Decoding Viatris Inc (VTRS): A Strategic SWOT Insight (GuruFocus.com)
Aug-08-24 04:02PM	Analyst Report: Viatris Inc. (Morningstar Research) +6.51%
01:19PM	Midday stock movers: Warner Bros. sinks, Nvidia, Rivian, Eli Lilly up (TheStreet)
11:52AM	Why Viatris Stock Is Jumping Today (Motley Fool)
09:53AM	Viatris (VTRS) Q2 Earnings Outpace Estimates, Sales Miss (Zacks)

Viatris, Inc. is a global healthcare company, which engages in the provision of healthcare and pharmaceutical products. It provides medicines and treatments in various therapeutic areas such as cardiovascular, oncology, dermatology, eye care, gastroenterology, immunology, and women's healthcare. The firm operates through the following segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment consists of operations primarily in North America and Europe. The Greater China segment includes operations in mainland China, Taiwan, and Hong Kong. The JANZ segment covers operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses operations in developing markets and emerging economies including in Asia, the Middle East, South and Central America, Africa, and Eastern Europe. The company was founded on February 14, 2019 and is headquartered in Canonsburg, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FINNEY ELISHA W	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	37,832	Mar 05 07:00 PM
Le Goff Corinne	Chief Commercial Officer	Mar 04 '25	Option Exercise	0.00	37,894	0	36,721	Mar 05 07:00 PM
Campbell Paul	See Remarks	Mar 04 '25	Option Exercise	0.00	207,325	0	328,250	Mar 05 07:00 PM
Campbell Paul	See Remarks	Mar 03 '25	Option Exercise	0.00	19,348	0	144,590	Mar 05 07:00 PM
Vivaldi Coelho Rogerio	Director	Mar 04 '25	Option Exercise	0.00	21,691	0	21,691	Mar 05 07:00 PM
Smith Scott Andrew	Chief Executive Officer	Mar 04 '25	Option Exercise	0.00	96,431	0	266,825	Mar 05 07:00 PM
Smith Scott Andrew	Chief Executive Officer	Mar 03 '25	Option Exercise	0.00	146,700	0	221,178	Mar 05 07:00 PM
PARRISH MARK W	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	140,395	Mar 05 07:00 PM
Lyons Dillon JoEllen	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	77,691	Mar 05 07:00 PM
KORMAN HARRY	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	113,937	Mar 05 07:00 PM
Groothuis Leo Frans	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	40,350	Mar 05 07:00 PM
HIGGINS MELINA E	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	121,213	Mar 05 07:00 PM
Malik Rajiv	Director	Mar 04 '25	Option Exercise	0.00	892,603	0	1,407,415	Mar 05 07:00 PM
Malik Rajiv	Director	Mar 03 '25	Option Exercise	0.00	89,430	0	587,599	Mar 05 07:00 PM
CORNWELL W DON	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	80,342	Mar 05 07:00 PM
KILTS JAMES M	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	136,422	Mar 05 07:00 PM
MARK RICHARD A	Director	Mar 04 '25	Option Exercise	0.00	18,977	0	91,310	Mar 05 07:00 PM
Roman Brian	Chief Legal Officer	Mar 04 '25	Option Exercise	0.00	206,263	0	265,061	Mar 05 07:00 PM
Roman Brian	Chief Legal Officer	Mar 03 '25	Option Exercise	0.00	18,345	0	84,494	Mar 05 07:00 PM
Mistras Theodora	Chief Financial Officer	Mar 04 '25	Option Exercise	0.00	32,472	0	41,815	Mar 05 07:00 PM
Mistras Theodora	Chief Financial Officer	Jan 01 '25	Option Exercise	0.00	24,065	0	23,084	Jan 03 06:00 PM
Campbell Paul	See Remarks	Nov 11 '24	Sale	12.88	26,925	346,686	126,901	Nov 12 07:00 PM
Campbell Paul	Officer	Nov 11 '24	Proposed Sale	12.88	26,925	346,686		Nov 12 04:30 PM
Malik Rajiv	Director	Sep 12 '24	Sale	11.66	139,681	1,628,164	505,838	Sep 13 06:00 PM
Malik Rajiv	Director	Sep 12 '24	Sale	11.71	60,319	706,553	0	Sep 13 06:00 PM
Malik Rajiv	Director	Aug 30 '24	Sale	12.00	50,000	600,000	60,319	Aug 30 06:16 PM
Malik Rajiv	Director	Aug 28 '24	Sale	11.90	50,000	595,075	110,319	Aug 30 06:16 PM
Malik Rajiv	Director	Aug 21 '24	Sale	11.75	100,000	1,175,260	360,319	Aug 23 06:05 PM
Malik Rajiv	Director	Aug 23 '24	Sale	11.75	100,000	1,175,100	160,319	Aug 23 06:05 PM
Malik Rajiv	Director	Aug 22 '24	Sale	11.73	100,000	1,172,630	260,319	Aug 23 06:05 PM
Malik Rajiv	Director	Aug 20 '24	Proposed Sale	11.80	600,000	7,080,000		Aug 20 12:07 PM
Malik Rajiv	Director	Jun 14 '24	Sale	10.18	264,300	2,690,283	645,519	Jun 17 06:00 PM
Malik Rajiv	Director	Jun 13 '24	Sale	10.52	85,660	900,741	909,819	Jun 17 06:00 PM
Roman Brian	Chief Legal Officer	May 28 '24	Sale	10.38	89,419	928,429	67,723	May 28 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Viatris Inc

Upgrade your FINVIZ experience